These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 19714614)

  • 1. Case of anakinra as a steroid-sparing agent for gout inflammation.
    Gratton SB; Scalapino KJ; Fye KH
    Arthritis Rheum; 2009 Sep; 61(9):1268-70. PubMed ID: 19714614
    [No Abstract]   [Full Text] [Related]  

  • 2. Autoinflammation in 2010: expanding clinical spectrum and broadening therapeutic horizons.
    Ombrello MJ; Kastner DL
    Nat Rev Rheumatol; 2011 Feb; 7(2):82-4. PubMed ID: 21289614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is interleukin-1 blockade a therapeutic option for patients with palindromic rheumatism?
    Jeries H; Daood R; Naffaa ME
    Clin Rheumatol; 2024 Aug; 43(8):2715-2717. PubMed ID: 38949739
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful treatment of cutaneous-onset Erdheim-Chester disease with cobimetinib and anakinra.
    Aromolo IF; Moltrasio C; Maronese CA; Campochiaro C; Bonometti A; Berti E; Passoni E; Marzano A
    Clin Exp Dermatol; 2024 Apr; 49(5):523-525. PubMed ID: 38231013
    [No Abstract]   [Full Text] [Related]  

  • 5. Role of anakinra in patients with ST-elevation myocardial infarction.
    Liu XH; Zhang L
    Int J Cardiol; 2024 Sep; 411():132297. PubMed ID: 38936429
    [No Abstract]   [Full Text] [Related]  

  • 6. Chronic urticaria and arthritis with polyclonal IgA: rapid response and clinical remission with interleukin 1 blockade.
    Chu CQ
    J Rheumatol; 2010 Apr; 37(4):881-2. PubMed ID: 20360207
    [No Abstract]   [Full Text] [Related]  

  • 7. Interleukin-1 blockade for recurrent pericarditis: insights from the real-world experience.
    Lazaros G; Tsioufis K; Vassilopoulos D
    J Pediatr; 2023 Jul; 258():113354. PubMed ID: 36963480
    [No Abstract]   [Full Text] [Related]  

  • 8. In-perspective: the ARAMIS double-blind randomized placebo-controlled trial of anakinra for the treatment of acute myocarditis.
    Morrow DA; Verbrugge FH
    Eur Heart J Acute Cardiovasc Care; 2023 Sep; 12(9):627-628. PubMed ID: 37648656
    [No Abstract]   [Full Text] [Related]  

  • 9. Expression and characterization of recombinant IL-1Ra in Aspergillus oryzae as a system.
    Mahmoudi Azar L; Karaman E; Beyaz B; Göktan I; Eyüpoğlu AE; Kizilel S; Erman B; Gül A; Uysal S
    BMC Biotechnol; 2023 Jun; 23(1):15. PubMed ID: 37340430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of interleukin-1 in perinatal inflammation and its impact on transitional circulation.
    Owen JC; Garrick SP; Peterson BM; Berger PJ; Nold MF; Sehgal A; Nold-Petry CA
    Front Pediatr; 2023; 11():1130013. PubMed ID: 36994431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of the Interleukin-1 Family in Complications of Prematurity.
    Green EA; Garrick SP; Peterson B; Berger PJ; Galinsky R; Hunt RW; Cho SX; Bourke JE; Nold MF; Nold-Petry CA
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of anakinra in gouty arthritis: A case series and review of the literature.
    Jeria-Navarro S; Gomez-Gomez A; Park HS; Calvo-Aranda E; Corominas H; Pou MA; Diaz-Torne C
    Front Med (Lausanne); 2022; 9():1089993. PubMed ID: 36714095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review.
    Pisaniello HL; Fisher MC; Farquhar H; Vargas-Santos AB; Hill CL; Stamp LK; Gaffo AL
    Arthritis Res Ther; 2021 Apr; 23(1):130. PubMed ID: 33910619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Therapeutic Options in the Treatment of Rheumatoid Arthritis.
    Köhler BM; Günther J; Kaudewitz D; Lorenz HM
    J Clin Med; 2019 Jun; 8(7):. PubMed ID: 31261785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives.
    Lopalco G; Cantarini L; Vitale A; Iannone F; Anelli MG; Andreozzi L; Lapadula G; Galeazzi M; Rigante D
    Mediators Inflamm; 2015; 2015():194864. PubMed ID: 25784780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An expanding role for interleukin-1 blockade from gout to cancer.
    Dinarello CA
    Mol Med; 2014 Dec; 20 Suppl 1(Suppl 1):S43-58. PubMed ID: 25549233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging role of biotechnological drugs in the treatment of gout.
    Cavagna L; Taylor WJ
    Biomed Res Int; 2014; 2014():264859. PubMed ID: 24839602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of spontaneous resolution of acute gouty inflammation.
    Steiger S; Harper JL
    Curr Rheumatol Rep; 2014 Jan; 16(1):392. PubMed ID: 24343224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating inflammation by blocking interleukin-1 in humans.
    Dinarello CA; van der Meer JW
    Semin Immunol; 2013 Dec; 25(6):469-84. PubMed ID: 24275598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.
    Ramasamy SN; Korb-Wells CS; Kannangara DR; Smith MW; Wang N; Roberts DM; Graham GG; Williams KM; Day RO
    Drug Saf; 2013 Oct; 36(10):953-80. PubMed ID: 23873481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.